Related Experiment Videos
Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation
A Ugur Ural1, M Ilker Yilmaz, Ferit Avcu
1Department of Hematology, Gulhane Military Medical Academy, Ankara, Turkey. aural@gata.edu.tr
Insights
Cerivastatin, a cholesterol-lowering drug, improved lipid profiles and reduced platelet aggregation in patients with mixed hyperlipidemia. It also favorably impacted key hemostatic factors, suggesting broader cardiovascular benefits.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Background:
- Ischemic heart disease involves platelet activation, impaired fibrinolysis, coagulation, and dyslipidemia.
- Antiplatelet agents are commonly used in managing ischemic heart disease.
- Mixed hyperlipidemia contributes to cardiovascular risk.
Purpose of the Study:
- To assess the effects of cerivastatin on lipid levels and hemostatic variables in patients with primary mixed hyperlipidemia.
- To evaluate cerivastatin's impact on platelet aggregation and specific coagulation factors.
Main Methods:
- A study involving 20 patients with primary mixed hyperlipidemia.
- Treatment included a lipid-lowering diet, placebo, and cerivastatin.
- Measurements included lipid profiles, fibrinogen, coagulation factors (VII, VIII, X), plasminogen, antiplasmin, platelet count, and aggregation (ADP, collagen, epinephrine).
Main Results:
- Cerivastatin significantly reduced triglyceride, total cholesterol, and LDL cholesterol.
- Platelet aggregation induced by ADP, collagen, and epinephrine was significantly reduced.
- Factor VII and fibrinogen levels were significantly decreased post-cerivastatin treatment.
Conclusions:
- Cerivastatin demonstrates beneficial effects on lipid profiles in mixed hyperlipidemia.
- The drug also positively influences specific hemostatic variables and platelet aggregation.
- These findings suggest potential additional cardiovascular benefits beyond lipid-lowering.
Abstract:
Platelet activation, impairment of fibrinolysis, activation of the coagulation pathway, and dyslipidemia are important factors in the pathogenesis and progression of ischemic heart disease, and patients generally need to use an antiplatelet agent. Lipid-lowering cerivastatin, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, was administered to 20 patients with primary mixed hyperlipidemia for the assessment of the effect of cerivastatin on lipid levels, plasma fibrinogen concentration, factor VII, VIII, and X levels, plasminogen and antiplasmin concentrations, platelet count, and aggregation (adenosine diphosphate [ADP], collagen, and epinephrine induced). Assessments were made immediately after 2 months of a standard lipid-lowering diet, 4 weeks of placebo administration, and 4 weeks of cerivastatin treatment. Cerivastatin achieved significant reductions in triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels. The significant improvement of the lipid profile was associated with platelet aggregation reduction in vitro stimulated by ADP, collagen, and epinephrine (P < .05, P = .05, P < .005, respectively). Significantly lower levels of factor VII and fibrinogen were observed (P = .001, P < .0001) immediately after cerivastatin treatment. No significant differences were detected in factor VIII level, plasminogen and antiplasmin concentrations, and platelet count after cerivastatin treatment. It was concluded that cerivastatin in mixed hyperlipidemia can exert beneficial changes on specific hemostatic variables and platelet aggregation in addition to its positive effects on plasma lipid values.